Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1947848 | 0.84 | L3MBTL1 (0.72) | PTGDR2L3MBTL1TDP1LMNAMAPK1 | |
| SCHEMBL1753397 | 0.84 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL30537993 | 0.81 | L3MBTL1 (0.59) | PTGDR2L3MBTL1TDP1LMNAMAPK1 | |
| SCHEMBL1753771 | 0.81 | PTGDR2 (0.76) | PTGDR2TDP1 | |
| SCHEMBL2442473 | 0.80 | L3MBTL1 (0.58) | PTGDR2L3MBTL1TDP1LMNAMAPK1 | |
| SCHEMBL21497776 | 0.79 | KDM4E (0.59) | PTGDR2L3MBTL1LMNAMAPK1POLB | |
| SCHEMBL27688196 | 0.79 | L3MBTL1 (0.65) | PTGDR2L3MBTL1TDP1LMNAMAPK1 | |
| SCHEMBL4284626 | 0.78 | MMP2 (0.71) | PTGDR2MMP2POLBFFAR1 | |
| SCHEMBL7806644 | 0.78 | PTGDR2 (0.65) | PTGDR2L3MBTL1TDP1LMNAMAPK1 | |
| SCHEMBL1690406 | 0.78 | PTGDR2 (1.00) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210347763-A1 | BIARYL PIPERIDINE AMIDE COMPOUNDS AND METHODS OF USE THEREOF | ATHENEX, INC. | 2021-11-11 | — | — | US | disclosed |
| US-20200071305-A1 | BIARYL PIPERIDINE AMIDE COMPOUNDS AND METHODS OF USE THEREOF | OAKTREE FUND ADMINISTRATION, LLC | 2020-03-05 | — | — | US | disclosed |
| US-10450303-B2 | Biaryl piperidine amide compounds and methods of use thereof | ATHENEX, INC. (US) | 2019-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450303-B2 | Biaryl piperidine amide compounds and methods of use thereof | AADAC, PAICS, UGT2B7 | PTGDR2 670/4885L3MBTL1 3469/4885TDP1 1861/4885 |
| US-20210347763-A1 | BIARYL PIPERIDINE AMIDE COMPOUNDS AND METHODS OF USE THEREOF | AADAC, PAICS, UGT2B7 | PTGDR2 670/4885L3MBTL1 3469/4885TDP1 1861/4885 |
| US-20200071305-A1 | BIARYL PIPERIDINE AMIDE COMPOUNDS AND METHODS OF USE THEREOF | AADAC, PAICS, UGT2B7 | PTGDR2 670/4885L3MBTL1 3469/4885TDP1 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.